Who is sponsoring NCT05924568?

NCT05924568 is sponsored by Brandon Hathorn.

What drugs are being tested in NCT05924568?

Interventions in NCT05924568: Educational session with Keep Your Move in the Tube and PrimusRS.

What condition does NCT05924568 study?

NCT05924568 studies Coronary Artery Disease, Valve Disease, Heart.

Is NCT05924568 still recruiting?

NCT05924568 is currently completed. Last updated 3 July 2023.

Last reviewed 2023-07-03 · How we verify

NCT05924568

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of Strength Outcomes After Use of the PrimusRS for Specificity of Training in a Cardiac Rehabilitation Setting

Completed NA Last updated 3 July 2023

What this trial tests

NA trial testing Educational session with Keep Your Move in the Tube and PrimusRS in Coronary Artery Disease. Completed in 1 November 2022.

Timeline

13 May 2015

Primary endpoint
1 November 2022

1 November 2022

Quick facts

Lead sponsor	Brandon Hathorn
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Primary purpose	treatment
Start date	13 May 2015
Primary completion	1 November 2022
Estimated completion	1 November 2022

Drugs / interventions tested

Educational session with Keep Your Move in the Tube and PrimusRS

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Valve Disease, Heart — all drugs for Valve Disease, Heart →

Sponsor

Brandon Hathorn

Who can join

Adults 18 to 80, any sex, with Coronary Artery Disease or Valve Disease, Heart. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if performed force measurements yield a different recommended weight lifted during the sternotomy healing process than the traditional gold standard of 5 pounds. A secondary endpoint data obtained will be scores from the pre and post-activity questionnaires.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05924568 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brandon Hathorn
Last refreshed: 3 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05924568.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing